Bilici, AhmetUysal, MukreminMenekse, SerkanAkin, SemihYildiz, FatihTuran, MerveSezgin Goksu, Sema2023-01-122023-01-1220220735-79071532-4192https://doi.org/10.1080/07357907.2021.2017952https://hdl.handle.net/11454/77155Purpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.en10.1080/07357907.2021.2017952info:eu-repo/semantics/closedAccessEverolimusexemestanemetastatic breast cancerhormone receptor-positiveHER - negativeefficacyAromatase InhibitorsSurvivalMtorHr+ChemotherapySensitivityCombinationGuidelinesResistanceTherapiesArticle402199209WOS:0007342583000012-s2.0-8512180305534894960Q2Q4